Read full paper at: http://www.scirp.org/journal/PaperInformation.aspx?PaperID=50793#.VE8SF1fHRK0 Author(s) Photis Beris 1,2 , Monika Nagy 1 , Daniel Robert 1 , Kaveh Samii 1 , Tom McKee 3 , Jovita Schuler 4 Affiliation(s) 1 Division of Haematology, University Hospital of Geneva, Geneva, Switzerland . 2 Department of Haematology, Unilabs Coppet, Coppet, Switzerland . 3 Department of Pathology, CMU, Geneva, Switzerland . 4 Novartis Pharma Switzerland, Rotkreuz, Switzerland . ABSTRACT Background: Patients with stem cell myeloproliferative disorders have a particularly poor prognosis and limited treatment options, i.e . mainly aggressive chemotherapy or allogeneic stem cell transplantation. In 2004, Chen et al. reported a patient presenting a t(8;13) (p11;q12) cytogenic anomaly who responded positively to treatment with PKC412 (midostaurin), an oral multi-targeted tyrosine kinase inhibitor. Here...
Scientific Research Publishing